SLS supply chain intelligence for SELLAS Life Sciences Group, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CONSULTANTS | CONSULTANTS | 90% | expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials |
| CROS | CROS | 90% | expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials |
| INVESTIGATIVE-SITES | INVESTIGATIVE-SITES | 90% | expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MRK | Merck & Co., Inc. | 72% | dose cohort in the Phase 2a study and reported positive initial topline data. At that time, we also commenced enrollment in the 60 mg dose cohort with patients randomized to one of two groups, 60 mg … |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from SLS graph: dose cohort in the Phase 2a study and reported positive initial topline data. At that time, we also commenced enrollmen… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SLS-DEBT-12599 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2017-12-31. |
| SLS-DEBT | Debt stack $871,000 | 90% | Market cache reports total debt of $871,000. |
| SLS-DEBT-12598 | Warrants outstanding: 818900 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SLS-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 890,929; ownership 0.48%; value $4.6M; as of 2025-12-31. |
| SLS-OWNER-TWO-SIGMA-INVESTMENTS-LP | Two Sigma Investments, LP | 95% | 13F/ownership overlay lists Two Sigma Investments, LP; shares held 1,082,207; ownership 0.59%; value $5.6M; as of 2025-12-31. |
| SLS-OWNER-DAGCO-INC | Dagco, Inc. | 95% | 13F/ownership overlay lists Dagco, Inc.; shares held 1,028,780; ownership 0.56%; value $5.3M; as of 2026-03-31. |
| SLS-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 8,467,400; ownership 4.59%; value $43.6M; as of 2025-12-31. |
| SLS-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 3,077,337; ownership 1.67%; value $15.8M; as of 2025-12-31. |
| SLS-OWNER-MARSHALL-WACE-LLP | Marshall Wace LLP | 95% | 13F/ownership overlay lists Marshall Wace LLP; shares held 1,340,668; ownership 0.73%; value $6.9M; as of 2025-12-31. |
| SLS-OWNER-MILLENNIUM-MANAGEMENT-LLC | Millennium Management Llc | 95% | 13F/ownership overlay lists Millennium Management Llc; shares held 1,387,849; ownership 0.75%; value $7.1M; as of 2025-12-31. |
| SLS-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 7,541,054; ownership 4.09%; value $38.8M; as of 2025-12-31. |
| SLS-OWNER-STATE-STREET-CORPORATION | State Street Corporation | 95% | 13F/ownership overlay lists State Street Corporation; shares held 2,188,171; ownership 1.19%; value $11.3M; as of 2025-12-31. |
| SLS-OWNER-NORTHERN-TRUST-CORPORATION | Northern Trust Corporation | 95% | 13F/ownership overlay lists Northern Trust Corporation; shares held 930,750; ownership 0.50%; value $4.8M; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| MRK | Merck & Co., Inc. | 100.00 | 1 | ['customer'] |
| BNBX | BNB Plus Corp. | 50.00 | 2 | |
| ADAG | Adagene Inc. | 50.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 50.00 | 2 | |
| IMMP | Immutep Limited | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 50.00 | 2 | |
| PSNL | Personalis, Inc. | 50.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 50.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 50.00 | 2 | |
| ORANY | ORANGE | 50.00 | 2 | |
| GYRE | Gyre Therapeutics, Inc. | 50.00 | 2 | |
| SDGR | Schrödinger, Inc. | 50.00 | 2 | |
| EVFM | Evofem Biosciences, Inc. | 50.00 | 2 | |
| DKS | DICK'S Sporting Goods, Inc. | 50.00 | 2 | |
| ELAN | Elanco Animal Health Incorporated | 50.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 50.00 | 2 | |
| VNDA | Vanda Pharmaceuticals Inc. | 50.00 | 2 | |
| ENZN | Viskase Companies, Inc. | 50.00 | 2 | |
| EXOZ | eXoZymes, Inc. | 50.00 | 2 |